Myelofibrosis is an inflammation-driven systemic disease in which cytokines, fibrosis and clonal evolution are inextricably linked. New data show that the control of inflammation has a decisive influence on the course of the disease. Modern therapies that simultaneously modulate JAK signaling pathways, hepcidin regulation and inflammatory networks mark a real paradigm shift.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Advanced Thyroid Cancer
Molecular Mechanisms and New Therapeutic Approaches
- Epidermolysis bullosa
Promoting Wound Healing with Gene Therapies and Birch Bark Extract
- From Risk Identification to Anti-Inflammatory Intervention
Inflammation as a Treatment Goal in Its Own Right
- Psoriasis Research: What's in the Pipeline?
Highly selective oral TYK inhibitors in Phase III
- Cardiometabolism
Retatrutid and the TRIUMPH Program: The Triple Agonist on the Horizon
- Pediatric Retinoblastoma
The Tumor Microenvironment and Modern Eye-Sparing Therapies
- Adherence and management in asthma and COPD
Better to listen to the pharmacist
- Focus Update 2026